A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)
- Author
- KÜHR, T1 ; BURGSTALLER, S1 ; PONT, J8 ; KÖCK, L9 ; ABBREDERIS, K10 ; BALDINGER, C1 ; BUDER, R11 ; GEISSLER, D12 ; HAUSMANINGER, H13 ; LANG, A14 ; ZABERNIGG, A15 ; DUBA, C16 ; APFELBECK, U2 ; HILBE, W17 ; EISTERER, W17 ; FIEGL, M17 ; GREIL, R17 ; GASTL, G17 ; THALER, J1 ; LINKESCH, W2 ; SEEWANN, H3 ; FRIDRIK, M4 ; MICHLMAYR, G5 ; KRIEGER, O6 ; LUTZ, D6 ; LING, W7
[1] Department of Internal Medicine, General Hospital, Grieskirchnerstr, 42, Wels 4600, Austria
[2] Department of Internal Medicine, University Hospital, Graz, Austria
[3] Department of Internal Medicine, General Hospital, Fürstenfeld, Austria
[4] Department of Internal Medicine, General Hospital, Linz, Austria
[5] Department of Internal Medicine, Hospital of the Sisters of Mercy, Linz, Austria
[6] Department of Internal Medicine, Hospital of the Elizabethans, Linz, Austria
[7] Department of Internal Medicine, State Hospital, Villach, Austria
[8] Department of Internal Medicine, Kaiser Franz Josef Hospital, Wien, Austria
[9] Department of Internal Medicine, County Hospital, Lienz, Austria
[10] Department of Internal Medicine, Municipal Hospital, Dornbirn, Austria
[11] Department of Internal Medicine, Hospital of the Brothers of Mercy, Linz, Austria
[12] Department of Internal Medicine, State Hospital, Klagenfurt, Austria
[13] Department of Internal Medicine, State Hospital, Salzburg, Austria
[14] Department of Internal Medicine, State Hospital, Feldkirch, Austria
[15] ° Department of Internal Medicine, County Hospital, Kufstein, Austria
[16] Department of Medical Biology and Human Genetics, University of Innsbruck, Innsbruck, Austria
[17] Department of Internal Medicine, University Hospital Innsbruck, Innsbruck, Austria
Austrian CML Study Group, Austria - Source
Leukemia research. 2003, Vol 27, Num 5, pp 405-411, 7 p ; ref : 16 ref
- CODEN
- LEREDD
- ISSN
- 0145-2126
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Elsevier Science, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- CML Cytarabine Hydroxyurea Interferon Randomised study
- Keyword (fr)
- Anticancéreux Antimétabolite Association médicamenteuse Chimiothérapie Chronique Cytarabine Hydroxycarbamide Immunothérapie Interféron alpha Leucémie myéloïde Phase initiale Pyrimidine nucléoside Traitement Cytokine Hémopathie maligne Myéloprolifératif syndrome
- Keyword (en)
- Antineoplastic agent Antimetabolic Drug combination Chemotherapy Chronic Cytarabine Hydroxycarbamide Immunotherapy Alpha interferon Chronic myelocytic leukemia Early phase Pyrimidine nucleoside Treatment Cytokine Malignant hemopathy Myeloproliferative syndrome
- Keyword (es)
- Anticanceroso Antimetabólito Asociación medicamentosa Quimioterapia Crónico Citarabina Hidroxicarbamida Inmunoterapia Interferón alfa Leucemia mieloidea Fase inicial Pirimidina nucleósido Tratamiento Citoquina Hemopatía maligna Mieloproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 14685849
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0145-2126(02)00223-0 
https://dx.doi.org/10.1016/S0145-2126(02)00223-0
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0145-2126(02)00223-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:9:\"\u0000*\u0000jtitle\";s:17:\"Leukemia research\";s:9:\"\u0000*\u0000stitle\";s:9:\"Leuk. res\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"405\";s:8:\"\u0000*\u0000epage\";s:3:\"411\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0145-2126\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"K\u00dcHR\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:14:\"BURGSTALLER, S\";i:1;s:7:\"PONT, J\";i:2;s:8:\"K\u00d6CK, L\";i:3;s:13:\"ABBREDERIS, K\";i:4;s:12:\"BALDINGER, C\";i:5;s:8:\"BUDER, R\";i:6;s:11:\"GEISSLER, D\";i:7;s:15:\"HAUSMANINGER, H\";i:8;s:7:\"LANG, A\";i:9;s:12:\"ZABERNIGG, A\";i:10;s:7:\"DUBA, C\";i:11;s:12:\"APFELBECK, U\";i:12;s:8:\"HILBE, W\";i:13;s:11:\"EISTERER, W\";i:14;s:8:\"FIEGL, M\";i:15;s:8:\"GREIL, R\";i:16;s:8:\"GASTL, G\";i:17;s:9:\"THALER, J\";i:18;s:11:\"LINKESCH, W\";i:19;s:10:\"SEEWANN, H\";i:20;s:10:\"FRIDRIK, M\";i:21;s:12:\"MICHLMAYR, G\";i:22;s:10:\"KRIEGER, O\";i:23;s:7:\"LUTZ, D\";i:24;s:7:\"LING, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEREDD\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0145-2126(02)00223-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:9:\"\u0000*\u0000jtitle\";s:17:\"Leukemia research\";s:9:\"\u0000*\u0000stitle\";s:9:\"Leuk. res\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"405\";s:8:\"\u0000*\u0000epage\";s:3:\"411\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0145-2126\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"K\u00dcHR\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:14:\"BURGSTALLER, S\";i:1;s:7:\"PONT, J\";i:2;s:8:\"K\u00d6CK, L\";i:3;s:13:\"ABBREDERIS, K\";i:4;s:12:\"BALDINGER, C\";i:5;s:8:\"BUDER, R\";i:6;s:11:\"GEISSLER, D\";i:7;s:15:\"HAUSMANINGER, H\";i:8;s:7:\"LANG, A\";i:9;s:12:\"ZABERNIGG, A\";i:10;s:7:\"DUBA, C\";i:11;s:12:\"APFELBECK, U\";i:12;s:8:\"HILBE, W\";i:13;s:11:\"EISTERER, W\";i:14;s:8:\"FIEGL, M\";i:15;s:8:\"GREIL, R\";i:16;s:8:\"GASTL, G\";i:17;s:9:\"THALER, J\";i:18;s:11:\"LINKESCH, W\";i:19;s:10:\"SEEWANN, H\";i:20;s:10:\"FRIDRIK, M\";i:21;s:12:\"MICHLMAYR, G\";i:22;s:10:\"KRIEGER, O\";i:23;s:7:\"LUTZ, D\";i:24;s:7:\"LING, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEREDD\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0145-2126(02)00223-0\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0145-2126(02)00223-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:9:\"\u0000*\u0000jtitle\";s:17:\"Leukemia research\";s:9:\"\u0000*\u0000stitle\";s:9:\"Leuk. res\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"405\";s:8:\"\u0000*\u0000epage\";s:3:\"411\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0145-2126\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"K\u00dcHR\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:14:\"BURGSTALLER, S\";i:1;s:7:\"PONT, J\";i:2;s:8:\"K\u00d6CK, L\";i:3;s:13:\"ABBREDERIS, K\";i:4;s:12:\"BALDINGER, C\";i:5;s:8:\"BUDER, R\";i:6;s:11:\"GEISSLER, D\";i:7;s:15:\"HAUSMANINGER, H\";i:8;s:7:\"LANG, A\";i:9;s:12:\"ZABERNIGG, A\";i:10;s:7:\"DUBA, C\";i:11;s:12:\"APFELBECK, U\";i:12;s:8:\"HILBE, W\";i:13;s:11:\"EISTERER, W\";i:14;s:8:\"FIEGL, M\";i:15;s:8:\"GREIL, R\";i:16;s:8:\"GASTL, G\";i:17;s:9:\"THALER, J\";i:18;s:11:\"LINKESCH, W\";i:19;s:10:\"SEEWANN, H\";i:20;s:10:\"FRIDRIK, M\";i:21;s:12:\"MICHLMAYR, G\";i:22;s:10:\"KRIEGER, O\";i:23;s:7:\"LUTZ, D\";i:24;s:7:\"LING, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEREDD\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0145-2126(02)00223-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:9:\"\u0000*\u0000jtitle\";s:17:\"Leukemia research\";s:9:\"\u0000*\u0000stitle\";s:9:\"Leuk. res\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"405\";s:8:\"\u0000*\u0000epage\";s:3:\"411\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0145-2126\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"K\u00dcHR\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:14:\"BURGSTALLER, S\";i:1;s:7:\"PONT, J\";i:2;s:8:\"K\u00d6CK, L\";i:3;s:13:\"ABBREDERIS, K\";i:4;s:12:\"BALDINGER, C\";i:5;s:8:\"BUDER, R\";i:6;s:11:\"GEISSLER, D\";i:7;s:15:\"HAUSMANINGER, H\";i:8;s:7:\"LANG, A\";i:9;s:12:\"ZABERNIGG, A\";i:10;s:7:\"DUBA, C\";i:11;s:12:\"APFELBECK, U\";i:12;s:8:\"HILBE, W\";i:13;s:11:\"EISTERER, W\";i:14;s:8:\"FIEGL, M\";i:15;s:8:\"GREIL, R\";i:16;s:8:\"GASTL, G\";i:17;s:9:\"THALER, J\";i:18;s:11:\"LINKESCH, W\";i:19;s:10:\"SEEWANN, H\";i:20;s:10:\"FRIDRIK, M\";i:21;s:12:\"MICHLMAYR, G\";i:22;s:10:\"KRIEGER, O\";i:23;s:7:\"LUTZ, D\";i:24;s:7:\"LING, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEREDD\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0145-2126(02)00223-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:9:\"\u0000*\u0000jtitle\";s:17:\"Leukemia research\";s:9:\"\u0000*\u0000stitle\";s:9:\"Leuk. res\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"405\";s:8:\"\u0000*\u0000epage\";s:3:\"411\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0145-2126\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"K\u00dcHR\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:14:\"BURGSTALLER, S\";i:1;s:7:\"PONT, J\";i:2;s:8:\"K\u00d6CK, L\";i:3;s:13:\"ABBREDERIS, K\";i:4;s:12:\"BALDINGER, C\";i:5;s:8:\"BUDER, R\";i:6;s:11:\"GEISSLER, D\";i:7;s:15:\"HAUSMANINGER, H\";i:8;s:7:\"LANG, A\";i:9;s:12:\"ZABERNIGG, A\";i:10;s:7:\"DUBA, C\";i:11;s:12:\"APFELBECK, U\";i:12;s:8:\"HILBE, W\";i:13;s:11:\"EISTERER, W\";i:14;s:8:\"FIEGL, M\";i:15;s:8:\"GREIL, R\";i:16;s:8:\"GASTL, G\";i:17;s:9:\"THALER, J\";i:18;s:11:\"LINKESCH, W\";i:19;s:10:\"SEEWANN, H\";i:20;s:10:\"FRIDRIK, M\";i:21;s:12:\"MICHLMAYR, G\";i:22;s:10:\"KRIEGER, O\";i:23;s:7:\"LUTZ, D\";i:24;s:7:\"LING, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEREDD\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomized study comparing interferon (IFN\u03b1) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
